A new report by the Grattan Institute has accused the Pharmacy Guild of Australia of leveraging its political influence to secure opaque pricing arrangements that benefit community pharmacists at the expense of patients and the federal government.
The study highlights that Australia’s approximately 6,000 community pharmacies are being overpaid for dispensing medicines due to a lack of transparency in how these fees are negotiated.
The Grattan Institute argues that these backdoor deals prevent the government from effectively managing healthcare costs, a critical issue as the nation grapples with persistent inflationary pressures.
The findings come as global scrutiny on pharmaceutical pricing intensifies.
In a related development, the United States has initiated a formal investigation into Germany’s pharmaceutical pricing framework, citing concerns over underpayment for medicines as Berlin attempts to curb spiraling healthcare expenditures.
This suggests a broader international trend toward re-evaluating how drug distribution and dispensing are compensated.